{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=26",
    "query": {
      "intervention": "Formulation #2",
      "page": 26
    },
    "page_size": 10
  },
  "pagination": {
    "page": 26,
    "page_size": 10,
    "total_count": 1743,
    "total_pages": 175,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=27&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=25&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-03T10:19:17.473Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02831855",
      "title": "Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "CP-690,550",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 694,
      "start_date": "2016-09-01",
      "completion_date": "2018-12-17",
      "has_results": true,
      "last_update_posted_date": "2019-12-04",
      "last_synced_at": "2026-11-03T10:19:17.473Z",
      "location_count": 59,
      "location_summary": "Huntsville, Alabama • Gilbert, Arizona • Peoria, Arizona + 48 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Fair Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02831855"
    },
    {
      "nct_id": "NCT03618355",
      "title": "Trial of eRapa in Prostate Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "eRapa (encapsulated rapamycin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rapamycin Holdings, Inc. dba Emtora Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 15,
      "start_date": "2018-08-28",
      "completion_date": "2019-12-02",
      "has_results": false,
      "last_update_posted_date": "2020-03-31",
      "last_synced_at": "2026-11-03T10:19:17.473Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03618355"
    },
    {
      "nct_id": "NCT03389893",
      "title": "Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Atopic Dermatitis (AD)"
      ],
      "interventions": [
        {
          "name": "Dupilumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 72,
      "start_date": "2018-07-25",
      "completion_date": "2020-09-09",
      "has_results": true,
      "last_update_posted_date": "2021-10-04",
      "last_synced_at": "2026-11-03T10:19:17.473Z",
      "location_count": 9,
      "location_summary": "La Jolla, California • Los Angeles, California • Stanford, California + 6 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03389893"
    },
    {
      "nct_id": "NCT04676126",
      "title": "Augmented Macular Pigment-containing Nutraceutical and Central Visual Function",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma",
        "Glaucoma Eye",
        "Glaucoma, Open-Angle"
      ],
      "interventions": [
        {
          "name": "Lumega-Z",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Dorzolamide Hcl 2% Oph Soln",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of the Incarnate Word",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-05",
      "completion_date": "2022-05",
      "has_results": false,
      "last_update_posted_date": "2022-10-04",
      "last_synced_at": "2026-11-03T10:19:17.473Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04676126"
    },
    {
      "nct_id": "NCT04065633",
      "title": "Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dermatitis, Atopic"
      ],
      "interventions": [
        {
          "name": "P3-Fast",
          "type": "DRUG"
        },
        {
          "name": "Comm-Fast",
          "type": "DRUG"
        },
        {
          "name": "Vari-Fast",
          "type": "DRUG"
        },
        {
          "name": "Comm-Fed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 46,
      "start_date": "2019-07-18",
      "completion_date": "2019-12-14",
      "has_results": false,
      "last_update_posted_date": "2020-01-07",
      "last_synced_at": "2026-11-03T10:19:17.473Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04065633"
    },
    {
      "nct_id": "NCT01198626",
      "title": "Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Community-Acquired Bacterial Pneumonia (CABP)"
      ],
      "interventions": [
        {
          "name": "JNJ-32729463",
          "type": "DRUG"
        },
        {
          "name": "moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "JNJ-32729463 (Open-Label)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Furiex Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 32,
      "start_date": "2010-10",
      "completion_date": "2011-10",
      "has_results": false,
      "last_update_posted_date": "2011-12-08",
      "last_synced_at": "2026-11-03T10:19:17.473Z",
      "location_count": 13,
      "location_summary": "Mobile, Alabama • Sylmar, California • Orlando, Florida + 8 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Sylmar",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Vero Beach",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01198626"
    },
    {
      "nct_id": "NCT00858468",
      "title": "Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Influenza virus vaccine (2004-2005 Formulation)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "9 Months",
        "sex": "ALL",
        "summary": "2 Months to 9 Months"
      },
      "enrollment_count": 394,
      "start_date": "2005-04",
      "completion_date": "2006-12",
      "has_results": true,
      "last_update_posted_date": "2016-04-14",
      "last_synced_at": "2026-11-03T10:19:17.473Z",
      "location_count": 8,
      "location_summary": "Little Rock, Arkansas • Marietta, Georgia • Durham, North Carolina + 5 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Akron",
          "state": "Ohio"
        },
        {
          "city": "Dayton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00858468"
    },
    {
      "nct_id": "NCT01583530",
      "title": "Study of Belimumab Administered Subcutaneously to Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Single Dose Group: Belimumab IV 240 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Single Dose Group: Belimumab SC 2 x 120 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Single Dose Group: Belimumab SC 1 x 240 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Single Dose Group: Belimumab SC 1 x 200 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Multiple Dose Group: Belimumab SC 2 x 120 mg weekly",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Multiple Dose Group: Belimumab SC 1 x 200 mg weekly",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Human Genome Sciences Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 118,
      "start_date": "2011-02",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2013-08-07",
      "last_synced_at": "2026-11-03T10:19:17.473Z",
      "location_count": 4,
      "location_summary": "Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Evansville",
          "state": "Indiana"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01583530"
    },
    {
      "nct_id": "NCT00915837",
      "title": "Safety and Tolerability Study of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "triamcinolone acetonide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SurModics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2005-06",
      "completion_date": "2009-05",
      "has_results": false,
      "last_update_posted_date": "2023-06-09",
      "last_synced_at": "2026-11-03T10:19:17.473Z",
      "location_count": 4,
      "location_summary": "Phoenix, Arizona • Santa Barbara, California • Detroit, Michigan + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Edina",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00915837"
    },
    {
      "nct_id": "NCT06774131",
      "title": "A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Upper Urinary Tract Urothelial Carcinoma",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "UGN-104",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UroGen Pharma Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2025-08-06",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-11-03T10:19:17.473Z",
      "location_count": 34,
      "location_summary": "Homewood, Alabama • Chandler, Arizona • Queen Creek, Arizona + 30 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Queen Creek",
          "state": "Arizona"
        },
        {
          "city": "Arkansas City",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06774131"
    }
  ]
}